证券代码：300630 证券简称：普利退 公告编号：2025-055 债券代码：123099 债券简称：普利转退 海南普利制药股份有限公司 关于公司股票及可转换公司债券进入退市整理期交易的 第四次风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 券（以下简称"可转债"），于退市整理期届满的次一交易日摘牌，公司股票及 可转债终止上市。 最后交易日期为 2025 年 5 月 21 日。 月 14 日公司股票及可转债已交易 10 个交易日，剩余 5 个交易日，交易期满将 被终止上市，敬请投资者审慎投资、注意风险。 产重组。可转债在退市整理期的相关交易规则、投资者适当性安排请投资者查 阅《关于可转换公司债券退市整理期间交易安排的通知》（深证上〔2023〕492 号）及《关于完善可转换公司债券投资者适当性管理相关事项的通知（2025 年 修订）》（深证上〔2025〕223 号）。 约定购回、融资融券、转融通、深股通等业务。 务，建议有权机关在股票摘牌前通过原协助执行渠道提前办理续冻手续。 股票进入退市板块后，深股通投资者可能无法进行股票转让，提请 ...

Core Viewpoint - The significant decline in Feikai Convertible Bond and Huaxiang Convertible Bond is primarily due to the announcement of early redemption by both companies, leading to a negative conversion premium in the current market environment [1][4][5]. Group 1: Market Reaction - Feikai Convertible Bond dropped by 10.18%, closing at 113.534 CNY per bond, while Huaxiang Convertible Bond fell by 6.97%, closing at 122.764 CNY per bond [2]. - Both convertible bonds experienced a negative conversion premium, indicating a rapid decrease in their time value due to the early redemption announcements [1][4]. Group 2: Company Announcements - Feikai announced that from March 27 to April 25, its stock price had met the condition for early redemption, with 15 trading days closing above 120% of the conversion price of 15.30 CNY per share [4][5]. - Huaxiang similarly triggered its early redemption clause, with its stock price closing above 130% of the conversion price of 11.65 CNY per share for 15 out of 25 trading days [5]. Group 3: Implications of Early Redemption - The early redemption of convertible bonds reduces their time value, compressing the conversion premium to near zero, which negatively impacts bond prices [6]. - Investors are advised to closely analyze the terms of the bonds and adjust their positions to mitigate potential losses from the early redemption [1][6]. Group 4: Broader Market Concerns - Investors should also be aware of the potential delisting risks associated with convertible bonds, particularly as some underperforming companies may trigger delisting scenarios [7][8]. - The case of Puli Pharmaceutical illustrates the risks, as its stock and convertible bonds faced significant declines due to impending delisting, with the convertible bond dropping by 18.13% [8][10].